Sign In
Buy CUE
$26.91
-1.71 (-5.97%)
At Close: Jun 03, 2026
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
04:05pm, Tuesday, 02'nd Jun 2026
Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance an
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
04:05pm, Thursday, 21'st May 2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunol
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
04:07pm, Thursday, 14'th May 2026
Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering Moves designed to strengthen leadership and financial position,
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:07pm, Thursday, 07'th May 2026
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its new
Cue Biopharma Announces $30 Million Private Placement
04:25pm, Thursday, 30'th Apr 2026
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod
Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
Cue Biopharma Announces 1-for-30 Reverse Stock Split
08:37am, Wednesday, 22'nd Apr 2026
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
Cue Biopharma AGM: Shareholders Approve Reverse Stock Split, Elect Directors, Ratify Auditor
03:35am, Wednesday, 15'th Apr 2026
Cue Biopharma (NASDAQ: CUE) held its annual meeting of stockholders virtually, with Interim President and Chief Executive Officer Lucinda Warren presiding and outlining four proposals put before share
Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim
02:45pm, Friday, 10'th Apr 2026
The biopharmaceutical company is developing injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body.
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement
08:00am, Wednesday, 08'th Apr 2026
Preclinical milestone for selection and approval of first compound for lead optimization has been achieved Further development validates the potential intended mechanistic effect of CUE-501 for T cell
Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript
04:56pm, Tuesday, 07'th Apr 2026
Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases Transcript
Cue Biopharma Announces CEO Transition
04:05pm, Friday, 27'th Mar 2026
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
08:00am, Thursday, 26'th Mar 2026
Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
04:05pm, Monday, 16'th Mar 2026
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mo
